You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. EGFR Peptides as Vaccines in Anti-Tumor Immunity

    SBC: L2 DIAGNOSTICS LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Epidermal Growth Factor Receptor (EGFR) bearing tumors remain as one of the most insidious and difficult to treat human malignancies, affecting thousands of individuals each year. Our proposed studies are aimed at developing novel tumor immunotherapy by using both cryptic peptides of EGFR protein as well as isoaspartyl modified EGFR peptides, both of which brea ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien

    SBC: MABVAX THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The carbohydrate antigen sialyl-Lewis a (sLea) is widely expressed on epithelial tumors of the gastrointestinal tract, on breast cancer cells, and also on small cell lung cancer cells but is expressed minimally or not at all on normal tissues. sLea serves as a ligand for epithelial leukocyte adhesion molecules and higher expression of sLea was observed in patie ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A Home Exercise Program (DVD) for Women with Infants and Young Children

    SBC: KLEIN BUENDEL, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Becoming a mother is a significant transition in a woman's life. This transition can precipitate major changes in health behaviors, like physical activity. Once a woman has a child she is much less likely to participate in regular, moderate to vigorous physical activity compared to women without children. Thus, new mothers are at risk for future weight gain and ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Aptamer-based Glycomics Tools

    SBC: ECHELON BIOSCIENCES, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Protein glycosylation plays very important roles in biological processes. However, detecting and differentiating such modifications rapidly is not a trivial issue. Therefore, developing novel tools that allow for the rapid detection of glycosylation patterns is of tremendous importance to the field of glycomics. In this application, we propose to develop a nove ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Bio-monitoring Methylene Diphenyl Diisocyanate (MDI) exposure and body burden

    SBC: L2 DIAGNOSTICS LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Exposure to isocyanate, the essential cross-linker for making polyurethane, is a leading cause of occupational asthma world-wide. Three major types of isocyanate are used commercially, methylene-diphenyl diisocyanate (MDI) and toluene diisocyanate (TDI), or aliphatic, hexamethylene diisocyanate (HDI). Despite being the newest of the three, MDI has overtaken the ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Advancing clemizole for hepatitis C: towards a pre-IND package--Phase II

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is an important worldwide cause of liver disease. Current standard of care (SOC) agents are inadequate for most patients, and new virus-specific drugs are urgently needed. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We discovered that the HCV NS4B protein specifically binds a key segment of the HCV RN ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Risk Management in Developmental Disabilites

    SBC: PRAXIS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): The proposed project is designed to fill an extremely important yet unmet need by developing an alternative training mechanism that has the potential for reaching all personnel responsible for risk management and quality improvement in programs that provide services to persons with mental retardation/developmental disabilities (MRDD) and the public agency staff ...

    STTR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Human Lactoferrin in Acetaminophen Overdose-Induced Liver Failure

    SBC: VENTRIA BIOSCIENCE            Topic: NIAAA

    DESCRIPTION (provided by applicant): An acute or cumulative overdose of acetaminophen (APAP), following either therapeutic overdose or suicide attempts, can cause severe liver damage with the potential to progress to liver failure. APAP overdose accounts for more than 56,000 emergency room visits, 2,600 hospitalizations, and an estimated 458 deaths due to acute liver failure each year, making APAP ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. CSF Tau Biomarker-guided Development of Hsp90 Inhibitors for Alzheimer's Disease

    SBC: YUMA THERAPEUTICS CORPORAITON            Topic: NIA

    DESCRIPTION (provided by applicant): Research and Related Other Project Information Item 7. Project Summary/Abstract Neurodegeneration in Alzheimer's disease (AD) may result from deposition of A as plaques in brain tissue. However, less effort has been made to elucidate the role of tau- containing neurofibrillary tangles (NFTs) in AD. Accumulating evidence suggests that tau containing NFTs i ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. Drug regulators of nitric oxide production as Alzheimer's disease therapeutics

    SBC: Epigen Biosciences, Inc.            Topic: NIA

    DESCRIPTION (provided by applicant): Druggable regulators of nitric oxide production as new Alzheimer's disease therapeutics Summary: Nitrosative stress is a critical mediator of the onset and progression of Alzheimer's disease (AD): it precedes and is associated with neuritic dystrophy and dendritic spine loss, A /amyloid accumulation and deposition, cholinergic denervation and a memory ...

    STTR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government